| Grant number: | 21/02392-0 |
| Support Opportunities: | Scholarships in Brazil - Master |
| Start date: | September 01, 2021 |
| End date: | August 31, 2023 |
| Field of knowledge: | Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology |
| Principal Investigator: | Luiz Felipe Domingues Passero |
| Grantee: | Sarah Santos de Lima Melchert |
| Host Institution: | Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
Abstract Leishmaniasis is a non-contagious infectious disease caused by protozoa of the genus Leishmania that affect wild, domestic mammals, and humans. Among the species described, at least 20 are pathogenic to humans, and can cause different clinical manifestations such as visceral, mucocutaneous, and cutaneous leishmaniasis. The classic treatment of leishmaniasis is performed with pentavalent antimonial, amphotericin B, or miltefosine. However, side effects, high cost, constant medical monitoring, and low efficiency in some cases highlight the need to develop new safe, effective, topical, and low-cost drugs. Thus, the present work aims to evaluate the therapeutic effect of a topical cream containing 8-hydroxyquinoline in the cutaneous infections caused by Leishmania (Leishmania) amazonensis. Cationic and anionic creams containing 8-hydroxyquinoline will be formulated and skin absorption tests (in vitro) will be performed. The cream with the best absorption properties will be selected for the in vivo tests. BALB/c mice will be infected at the base of the tail and the cream will be topically applied during 15 days, once a day. After the last application, experimental animals will be euthanized, and cutaneous parasitism, as well as histological changes in the skin, will be quantified. | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |